Carisma Therapeutics, Inc. (CARM)
- Previous Close
1.4600 - Open
1.5000 - Bid 1.4300 x 200
- Ask 1.4700 x 100
- Day's Range
1.4300 - 1.5000 - 52 Week Range
1.4300 - 9.7660 - Volume
64,465 - Avg. Volume
172,427 - Market Cap (intraday)
61.18M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1200 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.83
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
www.carismatx.comRecent News: CARM
Performance Overview: CARM
Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CARM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CARM
Valuation Measures
Market Cap
60.65M
Enterprise Value
11.63M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.93
Price/Book (mrq)
5.57
Enterprise Value/Revenue
0.77
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.36%
Return on Equity (ttm)
-167.51%
Revenue (ttm)
15.07M
Net Income Avi to Common (ttm)
-81.22M
Diluted EPS (ttm)
-1.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
58.06M
Total Debt/Equity (mrq)
68.76%
Levered Free Cash Flow (ttm)
-53.14M
Research Analysis: CARM
Company Insights: CARM
CARM does not have Company Insights